Newsroom

NEW YORK--(BUSINESS WIRE)--Moody's Corporation (NYSE: MCO) will release its first quarter 2026 results before the start of NYSE trading on Wednesday, April 22, 2026. A copy of the earnings release and supplemental presentation slides will be posted on Moody's Investor Relations website, ir.moodys.com. Moody's Corporation invites you to participate in a teleconference with Rob Fauber, President, and Chief Executive Officer, and Noémie Heuland, Chief Financial Officer, to discuss its first quarte...

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) will hold a conference call to review results for its first quarter ended March 31, 2026. The public is invited to listen to the conference call on Friday, May 8, 2026, at 8:30 a.m. Eastern with Chief Executive Officer Jim Breuer and Chief Financial Officer John Regan. Financial results will be released prior to the market open that day. The live webcast and a replay will be available with accompanying slides online at investor.fluor...

KRUIBEKE, Belgium--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a global leader in space and defence technology solutions, announced today that it has been awarded a contract to develop a quantum-secure satellite under the European Space Agency’s (ESA) Quantum Key Distribution Satellite (QKDSat), within ESA’s Advanced Research in Telecommunications Systems (ARTES) Partnership Projects program. Redwire will manufacture and deliver its European-built Hammerhead spacecraft, equipped with the...

VANCOUVER, British Columbia--(BUSINESS WIRE)--WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce a strategic partnership with AliveCor, Inc. (“AliveCor”), the global leader in AI-powered personal electrocardiogram (ECG) technology, in which Canadian-registered cardiologists f...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo in Healthy Volunteers...

IRVINE, Calif.--(BUSINESS WIRE)--Mobix Labs, Inc. (Nasdaq: MOBX) (“Mobix Labs”), a rapidly growing fabless semiconductor and connectivity company serving the defense, aerospace, and high-reliability markets, today announced that its board of directors approved the Company’s 1-for-10 reverse stock split (the “Reverse Split”) of the Company’s Class A common stock, par value $0.00001 per share and Class B common stock, par value $0.00001 per share (collectively the “Common Stock”) . The Reverse Sp...

TORONTO--(BUSINESS WIRE)--Roots Corporation (“Roots” or the “Company”) (TSX: ROOT), the premium outdoor-lifestyle brand, today announced that the Company will host a conference call to discuss its fourth quarter and fiscal year 2025 results on Thursday, April 9, 2026. Ms. Meghan Roach, President & Chief Executive Officer and Mr. Leon Wu, Chief Financial Officer, will host the call. Fourth Quarter and Fiscal Year 2025 Results Conference Call Details DATE: Thursday, April 9, 2026    TIME: 8:0...

NEW YORK--(BUSINESS WIRE)--KKR, a leading global investment firm, today announced the final closing of KKR North America Fund XIV (“NAX4” or the “Fund”), an approximately $23 billion fund focused on pursuing opportunistic private equity investments in North America through a disciplined and consistent investment approach. NAX4 is the largest private equity fund raised that focuses on investing solely in North America. “We are grateful for the support we received for NAX4 and for the trust our i...

NEW YORK--(BUSINESS WIRE)--The Opus Group (“Opus”), a purpose-built network of agency brands delivering experiential, event, and brand marketing for more than 70 global companies, including some of the world's most influential brands, today announced that investment funds managed by EagleTree Capital (“EagleTree”) have acquired Opus from its previous partner, Growth Catalyst Partners. Terms of the transaction were not disclosed. Live and experiential marketing is playing an increasingly central...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. At this in...